AMPHASTAR JPM 2025_.pdf

1、J.P.Morgan Healthcare ConferenceJanuary 2025Highly Purified Peptide/ProteinProprietaryInjectables Inhalation IntranasalBiosimilar InterchangeableComplex Generic Combination Products2Forward Looking StatementsThis presentation and the accompanying oral presentation contain forward-looking statements,

2、of Amphastar Pharmaceuticals,Inc.(“Amphastar”,“we”.“our”and that are based on our managements current expectations and assumptions and on information currently available to management.Forward-looking statements include all statements other than statements of historical fact contained in this present

3、ation,including,but not limited to,information concerning our business plans and objectives,potential growth opportunities,product development,regulatory approvals,market potential,efficiencies,competitive position,and industry environment,among other statements.All statements in this presentation r

4、eferenced above that are not historical are forward-looking statements,including,among other things,statements relating to our expectations regarding future financial performance and business trends,our future growth,sales and marketing of our products,market size and expansion,product portfolio,pro

5、duct development,the timing of FDA filings or approvals,including the DMFs of ANP,the timing of product launches,acquisitions and other matters related to our pipeline of product candidates,the timing and results of clinical trials,the benefits of the acquisition of BAQSIMI,including its potential f

6、or continued revenue growth,the success of our integration of BAQSIMI,the transition of our pipeline towards branded products,proprietary products,and biosimilars,our ability to leverage our existing expertise and technology,and other future events.These statements are not facts but rather are based